Akari Therapeutics
AKTX
11 hedge funds and large institutions have $1.89M invested in Akari Therapeutics in 2022 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 1 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
0% more funds holding
Funds holding: 11 → 11 (0)
0% less ownership
Funds ownership: 0% → 0% (-0%)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
13% less capital invested
Capital invested by funds: $2.16M → $1.89M (-$271K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OFW
Omnia Family Wealth
Aventura,
Florida
|
+$120K |
| 2 |
HP
Hikari Power
Tokyo,
Japan
|
+$54.9K |
| 3 |
VF
Virtu Financial
New York
|
+$22.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$17.9K |
| 2 |
TC
Truvestments Capital
Sarasota,
Florida
|
-$2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
OFW
1
Omnia Family Wealth
Aventura,
Florida
| $910K | +$120K | +114 | +14% |
|
|
NMC
2
NEA Management Company
Timonium,
Maryland
| $543K | – | – | – |
|
|
HP
3
Hikari Power
Tokyo,
Japan
| $157K | +$54.9K | +52 | +46% |
|
|
BMCM
4
Bryn Mawr Capital Management
Philadelphia,
Pennsylvania
| $120K | – | – | – |
|
|
5
Renaissance Technologies
New York
| $56K | -$17.9K | -17 | -23% |
|
6
Geode Capital Management
Boston,
Massachusetts
| $36K | – | – | – |
|
|
CAN
7
Cetera Advisor Networks
El Segundo,
California
| $25K | – | – | – |
|
|
VF
8
Virtu Financial
New York
| $20K | +$22.2K | +21 | New |
|
9
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| $14K | – | – | – |
|
10
Morgan Stanley
New York
| $7K | – | – | – |
|
11
Bank of America
Charlotte,
North Carolina
| $4K | – | – | – |
|
|
TC
12
Truvestments Capital
Sarasota,
Florida
| – | -$2K | -2 | Closed |
|
AKTX Hedge Fund Activity: Q1 2022 in Review
11 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Akari Therapeutics (AKTX) for Q1 2022, worth a combined $1.89M — down 13% from $2.16M a quarter earlier.
Fund positioning in AKTX was balanced in Q1 2022: 1 fund opened new positions, 1 closed out, 2 added to existing stakes and 1 trimmed.
The largest buyer was Omnia Family Wealth, adding an estimated $120K. The largest seller was Renaissance Technologies, cutting an estimated $17.9K.
- 11 institutional investors held Akari Therapeutics (AKTX) as of Q1 2022, unchanged from Q4 2021.
- Funds reported $1.89M of Akari Therapeutics stock for Q1 2022, down 13% quarter-over-quarter.
- 1 fund opened new Akari Therapeutics positions in Q1 2022 and 1 closed out, a net change of 0 holders.
- The largest Akari Therapeutics buyer in Q1 2022 was Omnia Family Wealth, an estimated $120K added.
- The largest Akari Therapeutics seller in Q1 2022 was Renaissance Technologies, an estimated $17.9K sold.
Based on aggregated 13F filings for Q1 2022.